Molecular mechanisms of subtype-specific inhibition of neuronal T-type calcium channels by ascorbate MT Nelson, PM Joksovic, P Su, HW Kang, A Van Deusen, JP Baumgart, ... Journal of Neuroscience 27 (46), 12577-12583, 2007 | 145 | 2007 |
Discovery of small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia J Liu, C Yang, C Simpson, D DeRyckere, A Van Deusen, MJ Miley, ... ACS medicinal chemistry letters 3 (2), 129-134, 2012 | 103 | 2012 |
Molecular pharmacology of human Cav3. 2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs E Perez-Reyes, AL Van Deusen, I Vitko Journal of Pharmacology and Experimental Therapeutics 328 (2), 621-627, 2009 | 98 | 2009 |
Validation of High Throughput Screening Assays Against Three Subtypes of Cav3 T-Type Channels Using Molecular and Pharmacologic Approaches X Xie, AL Van Deusen, I Vitko, DA Babu, LA Davies, N Huynh, H Cheng, ... Assay and drug development technologies 5 (2), 191-204, 2007 | 69 | 2007 |
The molecular karyotype of 25 clinical-grade human embryonic stem cell lines MA Canham, A Van Deusen, DR Brison, PA De Sousa, J Downie, ... Scientific reports 5 (1), 17258, 2015 | 63 | 2015 |
Characterization of the gating brake in the I-II loop of Cav3. 2 T-type Ca2+ channels II Arias-Olguín, I Vitko, M Fortuna, JP Baumgart, S Sokolova, IA Shumilin, ... Journal of Biological Chemistry 283 (13), 8136-8144, 2008 | 50 | 2008 |
Prosocial effects of an oxytocin metabolite, but not synthetic oxytocin receptor agonists, in a mouse model of autism SS Moy, BL Teng, VD Nikolova, NV Riddick, CD Simpson, A Van Deusen, ... Neuropharmacology 144, 301-311, 2019 | 19 | 2019 |
A developmental atlas of somatosensory diversification and maturation in the dorsal root ganglia by single-cell mass cytometry AB Keeler, AL Van Deusen, IC Gadani, CM Williams, SM Goggin, AK Hirt, ... Nature neuroscience 25 (11), 1543-1558, 2022 | 9* | 2022 |
Quality compliance in the development of cell-based medicines in non-pharma environments I Oliver-Vila, AL van Deusen, R Palau, J Vives BMC Proceedings 9 (Suppl 9), P29, 2015 | 3 | 2015 |
UNC569 as novel small molecule mer receptor tyrosine kinase inhibitor for treatment of ALL S Christoph, D DeRyckere, S Sather, X Wang, D Kireev, W Janzen, J Liu, ... Blood 118 (21), 2589, 2011 | 3 | 2011 |
Sexual dimorphism in the dorsal root ganglia of neonatal mice identified by protein expression profiling with single-cell mass cytometry SA Vradenburgh, AL Van Deusen, AN Beachum, JM Moats, AK Hirt, ... Molecular and Cellular Neuroscience 126, 103866, 2023 | | 2023 |
Overview of Chemistry, Manufacturing, and Controls (CMC) for Pluripotent Stem Cell-Based Therapies AL Van Deusen, ME McGary Regenerative Medicine for Degenerative Muscle Diseases, 157-203, 2016 | | 2016 |
Commercial Opportunities for Induced Pluripotent Stem Cells AL Van Deusen, R Nasis Stem Cells Handbook, 177-199, 2013 | | 2013 |
Novel inhibitors of Mer kinase as potential anticancer agents in the treatment of acute lymphoblastic leukemia (ALL) W Zhang, J Liu, C Yang, C Jayakody, V Korboukh, CC Simpson, ... ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 242, 2011 | | 2011 |
Caliper Labchip Technology in the Parallel Development of Small Molecule Inhibitors of Tyro3, Axl and Mer (TAM) Kinases A Van Deusen, C Simpson, B Janzen, X Wang, H Patel, J Liu, D Kireev, ... | | 2009 |
Structure-function of the gating particle located in the I-II loop of T-type Ca2+ channels I Arias-Guin, I Vitko, S Sokolova, AL Van Deusen, L Tejada, JC Gomora, ... BIOPHYSICAL JOURNAL, 601A-601A, 2007 | | 2007 |